USE OF HYDROXYCHLOROQUINE IN PREGNANCY
Date of issue: July 2025, Version: 1.0
Hydroxychloroquine (HCQ) is a quinine derivative indicated for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, discoid and systemic lupus erythematosus (SLE), and dermatological conditions caused or aggravated by sunlight.
Guidance from the British Society for Rheumatology (BSR) states that HCQ can be used throughout pregnancy at doses of ≤400mg/day and is a drug of choice for women with rheumatic disease who are planning a pregnancy.
A single study found that daily doses of HCQ ≥400mg were associated with a 30% increase in risk of congenital malformation (equating to an ~4% malformation risk following exposure), whereas lower doses were not associated with increased risk. These data are likely confounded by maternal disease severity and are of limited relevance to most patients as HCQ doses above 400mg/day are not generally recommended for the treatment of rheumatic disease. The available data overall do not demonstrate that HCQ exposure in pregnancy increases the risks of miscarriage, stillbirth, preterm delivery (PTD), or low infant birth weight. Protective effects against PTD have been inconsistently observed. HCQ treatment of SLE and/or antiphospholipid syndrome during pregnancy has been associated with reduced disease flare and improved pregnancy and neonatal outcomes, including reductions in preterm birth, intrauterine death, neonatal lupus, and congenital heart block. There are limited but reassuring data relating to childhood neurodevelopment following HCQ exposure.
Exposure to HCQ at any stage in pregnancy would not usually be regarded as medical grounds for termination of pregnancy or any additional fetal monitoring. However, women with rheumatic disease may require closer monitoring during pregnancy including serial fetal growth measurement. Other risk factors which could independently increase the risk of adverse pregnancy outcome may also be present in individual cases and should be considered when performing case-specific risk assessments.
This is a summary of the full UKTIS monograph for health care professionals and should not be used in isolation. The full UKTIS monograph and access to any hyperlinked related documents is available to NHS health care professionals who are logged in.
If you have a patient with exposure to a drug or chemical and require assistance in making a patient-specific risk assessment, please telephone UKTIS on 0344 892 0909 to discuss the case with a teratology specialist.
If you would like to report a pregnancy to UKTIS please click here to download our pregnancy reporting form. Please encourage all women to complete an online reporting form.